Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-04-18
2006-04-18
Crouch, Deborah (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S185100
Reexamination Certificate
active
07030098
ABSTRACT:
A pro-inflammatory T cell response is specifically suppressed by the injection into a recipient of DNA encoding an autoantigen associated with autoimmune disease. The recipient may be further treating by co-vaccination with a DNA encoding a Th2 cytokine, particularly encoding IL4. In response to the vaccination, the proliferation of autoantigen-reactive T cells and the secretion of Th1 cytokines, including IL-2, IFN-γ and IL-15, are reduced.
REFERENCES:
patent: 5939400 (1999-08-01), Steinman et al.
patent: WO 97 45144 (1997-12-01), None
patent: WO 97 46253 (1997-12-01), None
Sobel et al, Neurochem Res. 19:915-921, 1994.
Klinman et al. The Journal of Immunology 158: 3635-3639, 1997.
Baker et al (Gene Therapy 10:844-853, 2003.
Ristori et al. (2000)Myelin Basic intramolecular spreading without disease progression in a patient with multiple sclerosis. J. of Neuroimmunology. 110:240-243.
Ellmerich et al. (2005) High Incidence of Spontaneous Disease in an HLA and TCR Transgenic Multiple Sclerosis Model. J. Immunol. 174: 1938-1946.
Elkman L. (2005) Voluntary Suspension of Tysabri Marketing. Letter, pp. 1-2.
Nowicka et al., “Protective effect of naked DNA immunization in experimental autoimmune encephalitis.” Journal of Neuroimmunology, vol. 90, No. 1, (Sep. 1, 1998), p. 102, abstract 582 XP001068792 ISSN: 0165-5728.
Ruiz et al., “Suppressive Immunization with DNA Encoding a Self-Peptide Prevents Autoimmune Disease: Modulation of T Cell Costimulation”, Journal of Immunology, vol. 162, No. 6, (Mar. 15, 1999), p. 3336-3341, XP002196043.
Coon et al., (1999), “DNA immunization to prevent autoimmune diabetes”,J. Clin. Invest., 104(2):189-94.
Garren et al., (2001), “Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune diease via deviation to the Th2 pathway”,Immunity, 15:15-22.
IFNB—MS—Study—Group (1995), “Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial”,Neurology, 45:1277-85.
Lisak, et al., (1983), “Effect of treatment with Copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE)”,J. Neurol. Sci.62:281-93.
Mikol, et al., (1990), “Structure and chromosomal location of the gene for the oligodendrocyte-myelin glycoprotein”,J. Cell Biol., 111(6 pt 1):2673-2679.
Sela, and Teitelbaum, (2001), “Glatiramer acetate in the treatment of multiple sclerosis”,Expert Opin. Pharmacother., 2:1149-1165.
Steinman, (1990), “The use of monoclonal antibodies for treatment of autoimmune disease”,J. Clin. Immunol., 10(6):30S-38S; discussion 38S-39S.
Urbanek-Ruiz, et al., (2001), “Immunization with DNA encoding an immunodominant peptide of insulin prevents diabetes in NOD mice”,Clin. Immunol., 100:164-171.
Van Oosten, et al., (1997), “Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR- monitored phase II trial”,Neurology, 49:351-357.
Wiest-Ladenburger, et al., (1998), “DNA vaccination with glutamic acid decarboxylase (GAD) generates a strong humoral immune response in BALB/c, C57BL/6, and in diabetes-prone NOD mice”,Horm. Metab. Res., 30(10):605-609.
Yasuda et al., “Interferon beta modulates experimental autoimmune encephalomyelitis by altering the pattern of cytokine secretion”,Immunol. Invest.28:115-126.
Anderton et al., European Journal of Immunology, Apr. 1998, vol. 28:1251-1261.
Barnett et al., Journal of Neuroimmunology, vol. 64:163-173.
Bebo et al., Journal of Neuroscience Research, vol. 45:680-689.
Cohen, et al., Hosp. Practice, May 1997, pp. 169-177.
Davis, et al., Human Mol. Genetics, 1993, V. 11, pp. 1847-1851.
Davis, et al., Vaccine, 1994 V. 12, No. 16, pp. 1503-1509.
Falo, et al., Nature Medicine, V. 4, No. 11, 11/98, pp. 1239-1240.
Greer, et al., J. of Immunology, V. 149, 8/92, pp. 783-788.
Kerlero de Rosbo, et al., J. of Autoimmunity, 1998, V. 11, pp. 287-299.
King, et al., Nature Medicine, V. 4, No. 11, Nov. 1998, pp. 1281-1286.
Krieg, et al., Trends in Microbiology, V. 6, No. 1, Jan. 1998, pp. 23-27.
Leadbetter, et al., J. of Immunology, Mar. 1998, 161, pp. 504-512.
Ledley, FD., Pharmaceutical Research, vol. 13:1595-1613.
Mor, et al., Am. Assoc. of Immunologists, 1995, V. 155, pp. 2039-2046.
Nicholson, et al., Proc. Natl. Acad. Sci., V. 94, Aug. 1997, pp. 9279-9284.
Offner, et al., J. of Immunology, 1998, V. 161, pp. 2187-2186.
Oksenberg, et al., Curr. Opinion in Immunology, 1990, V. 2, pp. 619-621.
Oksenberg, et al., Nature, V. 3662, Mar. 1993, pp. 68-70.
Pardoll, et al., Immunity, V. 3, Aug. 1995, pp. 165-169.
Rawshaw et al., Immunology and Cell Biology, vol. 75:409-413.
Sato et al., Science, vol. 273-352-354.
Syrengelas, et al., Nature Medicine, V. 2(9), Sep. 1996, pp. 1038-1041.
Tang, et al., Nature, V. 356, Mar. 1992, pp. 152-154.
Tsunoda et al., Journal of Neuropathology and Experimental Neurology, vol. 57(8):758-767.
Ulmer, et al., Current Opinion in Immunology, 1996, vol. 8, pp. 531-536.
Ulmer, et al., Science, V. 259, Mar. 1993, pp. 1745-1749.
Waisman, et al., Nature Medicine, V. 2(8), Aug. 1996, pp. 899-905.
Xu, et al., Immunology, V. 84, 1995, pp. 173-176.
Diehl, Hans-Josef, et al.; “Individual exons encode the integral membrane domains of human myelin proteollpid protein”,Proc. Natl. Acad. Sci.;1986, pp. 9807-9811, vol. 83.
Kamolz, John, et al.; “Identification of three forms of human myelin basic protein by cDNA cloning”,Proc. Natl. Acad. Sci.;1986; pp. 4962-4966; vol. 83.
Pham-Dinh, Danielle, et al.; “Characterization and expression of the cDNA coding for the human myelin/oligodendrocyte glycoprotein”,J. Neurochemistry; 1994, pp. 2353-2356, vol. 63.
Hilton, Adrienne A., et al.; “Characterization of cDNA and genomic clones encoding human myelin oligodendrocyte glycoprotein”,J. Neurochemistry; 1995; pp. 309-316, vol. 65.
Sato, Shuzo, et al.; “cDNA cloning and amino acid sequence for human myelin-associated glycoprotein”;Biochemical and Biophysical Research Communications: Sep. 29, 1989; pp. 1473-1480; vol. 163, No. 3.
Spagnol, G., et al., “Molecular cloning of human myelin-associated glycoprotein”,Journal of Neuroscience Research.; 1989; pp. 137-142; vol. 24.
Trotter, John L., et al.; “T cell recognition of myelin proteolipid protein and myelin proteolipid protein peptides in the peripheral blood of multiple sclerosis and control subjects”,Journal of Neuroimmunology; 1998; pp. 172-178; vol. 84.
Meinl, Edgar, et al.; “Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis—complexity of the response and dominance of nested epitopes due to recruitement of multiple T cell clones”;J. Clin. Invest.; 1993, pp. 2633-2643; vol. 92.
Martin, Roland, et al.; “Fine Specificity and HLA restrictions of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals”;The Journal of Immunology; 1990; pp. 540-548; vol. 145.
Wallstrom, Erik, et al.; “Increased reactivity to myelin oligodendrocyte peptides and epitope mapping in HLA DR2(15)+multiple sclerosis”,Eur. J. Immunol.; 1996; pp. 3329-3335, vol. 28.
Tuohy, Vincent K., et al.; “The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and mulitple sclerosis”;Immunological Reviews; 1998; pp. 93-100; vol. 164.
Takacs, Katalin, et al.; “The case against epitope spread in experimental allergic encephalomyelitis”,Immunological Review; 1998; pp. 101-110; vol. 164.
Takacs, Katalin, et al.; “Relapsing and remitting experimental allergic encephalomyelitis: a focused response to the encephalitogenic peptide rather than epitope spread”;Eur. J. Immunol.; 1997; pp. 2927-2934; vol. 27.
Tuohy, Vincent, et al.; “Spontaneous r
Garren Hideki
Ruiz Pedro
Steinman Lawrence
Crouch Deborah
Lieto Louis D
The Board of Trustees of the Leland Stanford Junior University
Townsend & Townsend & Crew LLP
LandOfFree
DNA vaccination for treatment of autoimmune disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with DNA vaccination for treatment of autoimmune disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DNA vaccination for treatment of autoimmune disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3560727